New IMCgp100-102 Data Show Durable Response and Robust Overall Survival Rate in Patients with Metastatic Uveal Melanoma
Patients with metastatic uveal melanoma (mUM) treated with IMCgp100 continued to experience a durable tumour response with a median follow up of 19.1 months, without yet reaching median overall survival (OS), according to new Phase I research to be presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.2 IMCgp100 is the wholly-owned, lead programme from Immunocore Limited, a leading T-cell receptor (TCR) company focused on delivering first-in-class biological therapies that transform lives.
Although rare, uveal melanoma is the most common form of adult eye cancer.3 When it metastasises beyond the eye, less than half of patients will survive for one year.4 Of the 19 HLA-A*0201+ patients enrolled in Phase I of the Phase I/II dose escalation trial, 17 were evaluated for efficacy. Among these patients, treatment with IMCgp100 was associated with an objective response rate of 18% (90% confidence interval [4,30]) and a one-year overall survival rate of 74% (95% confidence interval [48,88]) at the time of data cut-off.2
“Survival rates in uveal melanoma have remained largely unchanged for decades, and it is difficult to treat once it advances to metastatic disease,” said Dr. Takami Sato, Department of Medical Oncology, Kimmel Cancer Center, Thomas Jefferson University and lead investigator. “These data provide compelling evidence that IMCgp100 may offer hope to this underserved patient population.”
Additional exploratory survival analyses also indicated prolonged OS was associated with a number of pharmacodynamic outcomes, including lymphocyte trafficking, providing encouraging evidence supporting the proposed mechanism of action of IMCgp100.2
“Immunocore is focused on transforming the lives of patients with some of the most challenging diseases, such as metastatic uveal melanoma, for which there is currently no standard of care,” said Andrew Hotchkiss, Chief Executive Officer at Immunocore. “Although these are early findings, we are encouraged by the emerging clinical data and focused on advancing our pivotal trials.”
The most common adverse events in the Phase I arm included pruritus (severe itching of the skin; 90%), pyrexia (fever) and fatigue (84%), and hypotension (74%).2 Dose limiting toxicities were observed in 3 patients; all were reversible abnormalities in liver function tests (Grade 3 or 4 ALT/AST changes). There were no IMCgp100-related AEs that resulted in discontinuation or death.2
About Metastatic Uveal Melanoma
Uveal melanoma is an aggressive form of melanoma which affects the eye, with a poor prognosis and no standard of care.5 Although it is the most common primary intraocular malignancy in adults,3 the diagnosis is rare, with approximately 4,000 new patients diagnosed globally each year (1,500 cases/year in US).1 Up to 50% of people with uveal melanoma will eventually develop metastatic disease.5,6 When the cancer spreads beyond the eye, only approximately 40% of patients will survive for one year.4
About the IMCgp100-102 Phase I/II Trial
In this study, IMCgp100 is administered on a weekly basis with an intra-patient escalation dosing regimen. The dose escalation portion of the study has been completed, which identified the recommended Phase II intra-patient dose. The Phase II portion of the study is ongoing evaluating both the safety and efficacy in patients with metastatic uveal melanoma. The currently enrolling cohort is assessing IMCgp100 in patients who have experienced disease progression after 1 or 2 prior lines of therapy, which may include up to 1 line of liver directed therapy. Approximately 150 patients will be enrolled in the Phase II portion and the estimated enrolment completion date is September 2019.
About the IMCgp100 Programme
IMCgp100 is a novel bi-specific biologic T cell redirection therapy that specifically targets the melanoma-associated antigen gp100, and which is now in pivotal studies for mUM. IMCgp100 was granted Orphan Drug Designation by the US Food and Drug Administration in 2016 and Promising Innovative Medicine designation under UK Early Access to Medicines Scheme in 2017. For more information about enrolling IMCgp100 clinical trials for metastatic uveal melanoma, please visit ClinicalTrials.gov (NCT02570308 , NCT03070392).
About ImmTAC® Molecules
Immunocore’s proprietary TCR (T Cell Receptor) technology generates a novel class of bi-specific biologics called ImmTAC (Immune mobilising monoclonal TCRs Against Cancer) molecules that enable the immune system to recognise and kill cancerous cells. ImmTAC molecules are based on synthetic, soluble TCRs engineered to recognise intracellular cancer antigens with ultra-high affinity and selectively kill cancer cells via an anti-CD3 immune-redirecting effector function. ImmTAC molecules can access up to nine-fold more target antigens than typical antibody-based approaches, including monoclonal antibodies. Based on the demonstrated mechanism of T cell infiltration into human tumours, the ImmTAC mechanism of action holds the potential to tackle solid “cold” low mutation rate tumours, the majority of tumours that do not adequately respond to currently available immunotherapies.
Immunocore, a leading T Cell Receptor (TCR) biotechnology company, is focused on delivering first-in-class biological therapies that have the potential to transform the lives of people with serious diseases. The Company’s primary therapeutic focus is oncology and it also has programs in infectious and autoimmune diseases. Immunocore has a pipeline of proprietary and partnered programs in development and the lead programme, IMCgp100, has entered pivotal clinical studies as a treatment for patients with metastatic uveal melanoma. Partners include Genentech, GlaxoSmithKline, AstraZeneca, Lilly, and the Bill and Melinda Gates Foundation. Immunocore is headquartered at Milton Park, Oxfordshire, UK, with an office outside Philadelphia, USA. The Company is privately held by a broad international investor base. For more information, please visit www.immunocore.com.
|1||Data on file|
Sato, T. et al. Redirected T cell lysis in patients with metastatic uveal melanoma with gp100-directed TCR IMCgp100: Overall survival findings. Presented at ASCO 2018 (abstract 9521).
Mahendraraj K, Lau CS, Lee I, et al., 2016. Trends in incidence, survival, and management of uveal melanoma: a population-based study of 7,516 patients from the surveillance, epidemiology, and end results database (1973–2012). Clinical Ophthalmology, 10, 2113.
Khoja L, Atenafu E, Joshua A, and The International Rare Cancer's Initiative-Ocular Melanoma Group. 2016. Meta-analysis of phase II trials in metastatic uveal melanoma (MUM) to determine progression-free (PFS) and overall survival (OS) benchmarks for future phase II trials: An irci-ocular melanoma initiative. Journal of Clinical Oncology 34:15_suppl, 9567-9567.
Carvajal, RD, Schwartz, GK, Tezel, T, et al., 2017. Metastatic disease from uveal melanoma: treatment options and future prospects. British Journal of Ophthalmology, 101(1), 38-44.
Kujala E, Mäkitie T, Kivelä T. 2003. Very long-term prognosis of patients with malignant uveal melanoma. Investigative Ophthalmology & Visual Science, 44, 4651.
Andrew Hotchkiss, +44 (0) 1235 438600
Chief Executive Officer
Follow on Twitter: @Immunocore
Syneos Health Communications (IMCgp100)
Hannah Silver, 212-849-9483
Consilium Strategic Communications (corporate and financial)
Mary-Jane Elliott/Jessica Hodgson/Laura Thornton
+44 (0) 203 709 5700
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Gemalto and GlobalmatiX Go Full Speed with High Performance IoT Automotive Telematics13.12.2018 06:00 | Pressemelding
To meet growing demand for secure, high performance IoT telematics solutions, Gemalto and GlobalmatiX, a fully owned subsidiary of Softing AG, have teamed up to deliver an innovative solution that excelled in the grueling Porsche GT4 Cup championship race. The Gemalto Cinterion LTE Cat. 1 IoT Module and a Gemalto eSIM delivered secure, reliable wireless connectivity for the GlobalmatiX Telematics Control Unit (xTCU) enabling continuous monitoring, communications and remote predictive maintenance. The solution is available immediately to global OEMs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181212005599/en/ Automotive Telematics. Credit: GlobalmatiX Gemalto-enabled telematics device is racecar tested and approved Installed in a Porsche Cayman GT4 racecar, the Gemalto-enabled GlobalmatiX xTCU device was put to the test at Nürburgring racecourse, excelling under extreme conditions of heat, vibration and speeds of up to 28
Tilray® Announces International Advisory Board13.12.2018 05:01 | Pressemelding
Tilray, Inc. (NASDAQ:TLRY), a global pioneer in cannabis production and distribution, today announced the formation of its International Advisory Board, an esteemed group of business and government leaders who will provide guidance to Tilray’s executive team and Board of Directors as the company pursues its aggressive global growth strategy. “We are honored to welcome this impressive group of distinguished leaders to the Tilray team,” says Brendan Kennedy, Tilray CEO. “As we pioneer the future of our industry around the world, the experts on our International Advisory Board will advise us on our rapidly expanding global business.” Inaugural members of Tilray’s International Advisory Board include: Governor Howard Dean is a former Democratic National Committee (DNC) Chairman, presidential candidate, six-term Governor of Vermont, and physician. Gov. Dean is also the founder of Democracy for America, a lecturer at Yale University and a strategic consultant for the global law firm Dentons.
AIDUS Coin Successfully Raises Investment from CoinBene, the World's Leading Exchange13.12.2018 00:00 | Pressemelding
AISYS GLOBAL PTE. LTD. announced that it has received investment from CoinBene, one of the world’s leading crypto assets exchanges. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181212005153/en/ Investment contract ceremony between CoinBene and AISYS GLOBAL. Left: CoinBene CMO Daniel Lee. Right AISYS GLOBAL Founder Ted Min (Photo: Business Wire) AISYS GLOBAL is building the AIDUS Decentralized Fund Platform (ADFP), where users can subscribe to funds only via AIDUS coin. ADFP is the platform to connect investors and asset management companies with AIDUS coin without barriers of borders, language, currency. The most important part of the ADFP is the Smart QTS (Quant Trading System), which boasts an annual average return of 100% (as of December 1, 2018). Smart QTS is an automated trading program that has been validated through more than 15 years of development and over four years of operational performance. The weekly returns
The Epic Showdown Against the Black Mage Begins Now in MapleStory12.12.2018 22:12 | Pressemelding
MapleStory, the iconic free-to-play global MMORPG from Nexon, has launched the final chapter of the war with the game’s long-awaited villain, the Black Mage. The most anticipated clash event in Maple history brings two brand new Tenebris areas, an epic duel against Black Mage’s leading Commander Verus Hilla, and the monumental battle against the Black Mage himself. Players level 200 or higher who have completed the 5th job advancement can access the Labyrinth of Suffering, Tenebris’ second area. At the end of the quest, players will find Verus Hilla, one of the Black Mage’s leading Commanders, ready to fight. Limina, Tenebris’ final area, is also available as players must help the Tenebris expedition escape dangerous situations inside to complete the Journey of Destiny. In addition, every class will receive a new 5th job skill to fight the Black Mage and once the Maple Alliance gathers enough Determination to power up the Spark of Determination, all out war breaks loose as the highly a
Pacific Drilling Announces Relisting on NYSE12.12.2018 22:11 | Pressemelding
Pacific Drilling S.A. (OTC: PACDD) (the “Company”) today announced that it has received approval to relist its common shares on the New York Stock Exchange (“NYSE”) under the ticker symbol “PACD.” The Company expects that its common shares will commence trading on the NYSE at the market open on December 18, 2018. About Pacific Drilling With its best-in-class drillships and highly experienced team, Pacific Drilling is committed to becoming the industry’s preferred high-specification, deepwater drilling contractor. Pacific Drilling’s fleet of seven drillships represents one of the youngest and most technologically advanced fleets in the world. Pacific Drilling has its principal offices in Luxembourg and Houston. For more information about Pacific Drilling, including our current Fleet Status, please visit our website at www.pacificdrilling.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20181212005880/en/ Contact information Investor Contact: Johannes
IFF Declares Dividend for Fourth Quarter 201812.12.2018 21:20 | Pressemelding
Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF) (TASE:IFF), a leading innovator of scent, taste, and nutrition, announced that its Board of Directors has declared a regular quarterly cash dividend of $0.73 per share of its common stock, payable on January 7, 2019 to shareholders of record as of December 28, 2018. Meet IFF International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF) is a leading innovator of scent, taste, and nutrition, with over 110 manufacturing facilities, 100 R&D centers, and 33,000 customers globally. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what if?”. That passion for exploration drives us to co-create unique products that consumers experience in more than 150,000 unique products sold annually. Our 13,000 team members globally take advantage of leading consumer insights, naturals exploration, research and development, creative expertise, and customer inti